跳至主要内容
临床试验/NCT07270887
NCT07270887招募中不适用

The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks (RICMO-ASCVD): a Prospective, Blinded Endpoint, Multi-center, Cohort Study

General Hospital of Shenyang Military Region1 个研究点 分布在 1 个国家目标入组 2,800 人开始时间: 2025年11月19日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
2,800
试验地点
1
主要终点
Incidence of Composite Endpoint Events

研究概览

简要总结

Atherosclerotic cardiovascular disease (ASCVD) is a group of disorders sharing atherosclerosis as a common pathological basis, primarily affecting the heart, brain, kidneys, and other peripheral arteries, leading to clinical syndromes characterized mainly by arterial ischemia. It has become the group of diseases with the highest morbidity and mortality rates worldwide. Patients with very high-risk ASCVD face an even greater risk of recurrence. Previous studies have discovered that remote ischemic conditioning (RIC) has protective effects on major organs such as the heart, brain, and kidneys. Given the cardiorenal and cerebrovascular protective effects of RIC, the invesitgators believe that long-term remote ischemic conditioning is a promising approach to preventing the recurrence of ASCVD events. Based on this hypothesis, the investigators have designed a prospective, multicenter cohort study with blinded outcome assessment to investigate the protective effects of long-term remote ischemic conditioning in very high-risk ASCVD populations.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age over 40 years
  • Two or more prior major ASCVD events; OR one documented major ASCVD event with two or more of the following risk factors
  • signed informed consent
  • Note: Definition of Major ASCVD Events:
  • A. Acute coronary syndrome within the past year. B. History of myocardial infarction (not part of a new acute coronary syndrome episode).
  • C. Ischemic stroke or history of ischemic stroke. D. Symptomatic peripheral artery disease, defined as intermittent claudication with an ankle-brachial index (ABI) < 0.85, or prior limb revascularization or amputation.
  • Risk factors:
  • Heterozygous familial hypercholesterolemia
  • History of prior coronary artery bypass surgery or percutaneous coronary intervention outside of the major
  • ASCVD event(s)
  • Diabetes mellitus
  • Hypertension
  • CKD (eGFR 15-59 mL/min/1.73 m2)
  • Current smoking
  • Persistently elevated LDL-C (LDL-C ≥100 mg/dL [≥2.6 mmol/L]) despite maximally tolerated statin therapy and ezetimibe
  • History of congestive HF

排除标准

  • Presence of severe neurological deficit (mRS score ≥ 3)
  • Uncontrolled severe hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg despite medication)
  • Subclavian artery stenosis ≥ 50% or presence of subclavian steal syndrome
  • Severe hematological disorders or significant coagulation abnormalities
  • Contraindications to remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limbs, or peripheral vascular disease in the distal upper limbs
  • Severe comorbid conditions with a life expectancy of less than 1 year
  • Participation in another clinical trial within the past 3 months or ongoing participation
  • Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.

结局指标

主要结局

Incidence of Composite Endpoint Events

时间窗: 1 year

including cardiovascular events, stroke, vascular death, and deterioration of renal function.

次要结局

  • Occurence of vascular death(1 year)
  • Barthel Index (BI) scores(1 year)
  • Death due to all causes(1 year)
  • Number of participants with no-fatal cardiovascular events(1 year)
  • Number of participants with new onset diabetes(1 year)
  • Number of participants with no-fatal stroke(1 year)
  • Change of renal function(1 year)
  • Change of blood pressure(1 year)
  • Number of participants with no-fatal deterioration of renal function(1 year)
  • Changes in serological indicators such as blood glucose, blood lipids, and glycated hemoglobin (HbA1c)(1 year)

研究者

发起方
General Hospital of Shenyang Military Region
申办方类型
Other
责任方
Principal Investigator
主要研究者

Hui-Sheng Chen

Director

General Hospital of Shenyang Military Region

研究点 (1)

Loading locations...

相似试验

The Long-term Effect of Remote Ischemic Conditioning... | 临床试验